Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

NF1 drug development accelerates with novel treatments aiming to surpass current MEK inhibitors in efficacy, safety, and patient-friendly delivery. The evolving NF1 landscape highlights how innovation ...

NEW YORK, June 1, 2025 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm in the 2024 ISS ...

SpringWorks Therapeutics Inc. + Watchlist Alert SWTX US After Hours Last Updated: May 28, 2025 4:28 p.m. EDT Delayed quote $ 46.68 0.00 0.00% After Hours Volume: 300.35K Close Chg Chg % $46.68 0. ...

This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private ...

SpringWorks Therapeutics, Inc., a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced that the European Medicines Agency’s (EMA) Committee for Medicinal ...

In its first-quarter 2025 investor letter, Carillon Eagle Small Cap Growth Fund highlighted stocks such as SpringWorks Therapeutics, Inc. (NASDAQ:SWTX). Headquartered in Stamford, Connecticut ...

SpringWorks Therapeutics, a U.S.-based clinical-stage biopharmaceutical company, has been acquired by German pharmaceutical giant Merck KGaA in a $3.7 billion deal. Announced in early 2025, the ...

SpringWorks Therapeutics SWTX announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human ...

Year to date, shares of SpringWorks have risen 28.6% against the industry’s decline of 5.5%. In April 2025, Merck KGaA, Darmstadt, Germany, announced that it had agreed to acquire SpringWorks ...

DURHAM, N.C.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the opening of a new, $1 billion, 225,000-square-foot facility dedicated to ...